219 related articles for article (PubMed ID: 18979164)
1. Scintigraphic, biochemical, and clinical response to zoledronic acid treatment in patients with Paget's disease of bone.
Avramidis A; Polyzos SA; Moralidis E; Arsos G; Efstathiadou Z; Karakatsanis K; Grollios G; Kita M
J Bone Miner Metab; 2008; 26(6):635-41. PubMed ID: 18979164
[TBL] [Abstract][Full Text] [Related]
2. Long-Term Bone Scintigraphy Results After Intravenous Zoledronate in Paget's Disease of Bone.
Reid IR; Maslowski K
Calcif Tissue Int; 2017 Jul; 101(1):43-49. PubMed ID: 28324123
[TBL] [Abstract][Full Text] [Related]
3. Persistent effect of zoledronic acid in Paget's disease.
Tziomalos K; Florentin M; Krikis N; Perifanis V; Karagiannis A; Harsoulis F
Clin Exp Rheumatol; 2007; 25(3):464-6. PubMed ID: 17631747
[TBL] [Abstract][Full Text] [Related]
4. Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate.
Hosking D; Lyles K; Brown JP; Fraser WD; Miller P; Curiel MD; Devogelaer JP; Hooper M; Su G; Zelenakas K; Pak J; Fashola T; Saidi Y; Eriksen EF; Reid IR
J Bone Miner Res; 2007 Jan; 22(1):142-8. PubMed ID: 17032148
[TBL] [Abstract][Full Text] [Related]
5. Dual-energy X-ray absorptiometry and quantitative ultrasound in patients with Paget's disease of bone before and after treatment with zoledronic acid: association with serum bone markers and Dickkopf-1.
Polyzos SA; Anastasilakis AD; Litsas I; Sapranidis M; Efstathiadou Z; Kita M; Arsos G; Moralidis E; Zafeiriadou E; Papatheodorou A; Terpos E
J Clin Densitom; 2010; 13(2):190-6. PubMed ID: 20347367
[TBL] [Abstract][Full Text] [Related]
6. Treatment with tiludronate has a similar effect to risedronate on Paget's disease activity assessed by bone markers and bone scintigraphy.
Peris P; Alvarez L; Vidal S; Martínez MA; Monegal A; Guañabens N
Clin Exp Rheumatol; 2007; 25(2):206-10. PubMed ID: 17543143
[TBL] [Abstract][Full Text] [Related]
7. Serum osteoprotegerin and its ligand in Paget's disease of bone: relationship to disease activity and effect of treatment with bisphosphonates.
Alvarez L; Peris P; Guañabens N; Vidal S; Ros I; Pons F; Filella X; Monegal A; Muñoz-Gomez J; Ballesta AM
Arthritis Rheum; 2003 Mar; 48(3):824-8. PubMed ID: 12632438
[TBL] [Abstract][Full Text] [Related]
8. A review of Paget's disease of bone with a focus on the efficacy and safety of zoledronic acid 5 mg.
Abelson A
Curr Med Res Opin; 2008 Mar; 24(3):695-705. PubMed ID: 18226324
[TBL] [Abstract][Full Text] [Related]
9. Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease.
Reid IR; Miller P; Lyles K; Fraser W; Brown JP; Saidi Y; Mesenbrink P; Su G; Pak J; Zelenakas K; Luchi M; Richardson P; Hosking D
N Engl J Med; 2005 Sep; 353(9):898-908. PubMed ID: 16135834
[TBL] [Abstract][Full Text] [Related]
10. Normal bone turnover markers in a patient with active Paget's disease of bone: response to treatment with zoledronic acid.
Polyzos SA; Anastasilakis AD; Anagnostis P; Kita M; Arsos G; Moralidis E; Papatheodorou A; Terpos E
Endokrynol Pol; 2012; 63(4):312-5. PubMed ID: 22933168
[TBL] [Abstract][Full Text] [Related]
11. A single infusion of zoledronic acid produces sustained remissions in Paget disease: data to 6.5 years.
Reid IR; Lyles K; Su G; Brown JP; Walsh JP; del Pino-Montes J; Miller PD; Fraser WD; Cafoncelli S; Bucci-Rechtweg C; Hosking DJ
J Bone Miner Res; 2011 Sep; 26(9):2261-70. PubMed ID: 21638319
[TBL] [Abstract][Full Text] [Related]
12. Zoledronic acid: a review of its use in the treatment of Paget's disease of bone.
Keating GM; Scott LJ
Drugs; 2007; 67(5):793-804. PubMed ID: 17385948
[TBL] [Abstract][Full Text] [Related]
13. Bone turnover markers in Paget's disease of the bone: A Systematic review and meta-analysis.
Al Nofal AA; Altayar O; BenKhadra K; Qasim Agha OQ; Asi N; Nabhan M; Prokop LJ; Tebben P; Murad MH
Osteoporos Int; 2015 Jul; 26(7):1875-91. PubMed ID: 26037791
[TBL] [Abstract][Full Text] [Related]
14. Zoledronic acid for Paget's disease of bone.
Maricic M
Drugs Today (Barc); 2007 Dec; 43(12):879-85. PubMed ID: 18174973
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological therapy of Paget's and other metabolic bone diseases.
Hosking D
Bone; 2006 Feb; 38(2 Suppl 2):S3-7. PubMed ID: 16406763
[TBL] [Abstract][Full Text] [Related]
16. [Treatment of Paget's disease of bone with zoledronic acid].
Body JJ; Sternon J
Rev Med Brux; 2005; 26(6):513-7. PubMed ID: 16454155
[TBL] [Abstract][Full Text] [Related]
17. [Effect of a single dose of zoledronic acid in a case of Paget bone disease].
Saban M; Fidalgo S; Díaz CA; Lutfi RJ
Medicina (B Aires); 2010; 70(5):445-8. PubMed ID: 20920964
[TBL] [Abstract][Full Text] [Related]
18. The use of zoledronic acid for Paget's disease of bone.
Maricic M
Curr Osteoporos Rep; 2006 Mar; 4(1):40-4. PubMed ID: 16527007
[TBL] [Abstract][Full Text] [Related]
19. Profound hypocalcemia following effective response to zoledronic acid treatment in a patient with juvenile Paget's disease.
Polyzos SA; Anastasilakis AD; Litsas I; Efstathiadou Z; Kita M; Arsos G; Moralidis E; Papatheodorou A; Terpos E
J Bone Miner Metab; 2010 Nov; 28(6):706-12. PubMed ID: 20533067
[TBL] [Abstract][Full Text] [Related]
20. Remission over 3 years in patients with Paget disease of bone treated with a single intravenous infusion of 5 mg zoledronic acid.
Devogelaer JP; Geusens P; Daci E; Gielen E; Denhaerynck K; Macdonald K; Hermans C; Vancayzeele S; Abraham I; Boonen S
Calcif Tissue Int; 2014 Mar; 94(3):311-8. PubMed ID: 24271562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
